U.S. stocks closed higher, following positive momentum from Europe, as investors looked to Fed speeches and data for signals on rate hike timing.» Read More
Pharmaceuticals are priced at a bargain, said Mike Burnick, Weiss Capital Management director of research.
Stocks fell sharply Wednesday after the latest bevy of big names reporting earnings issued gloomy outlooks or missed their targets altogether.
Corporations are required to fund these pension funds at certain levels, and a lower market may require them to put up more money to cover any shortfall between what is paid out and what is taken in.
The cruel earnings season for the American worker intensified Wednesday as more companies announced layoffs.
You gotta feel sorry for the folks at Merck. Immediately after the drugmaker finishes a program to get rid of more than 10,000 employees, the company drops the ax again.
Stocks fell sharply at the open Wednesday after the latest bevy of big names reporting earnings issued gloomy outlooks or missed their targets altogether.
Stock index futures pointed to a weak open Wednesday as the emerging earnings picture did little to alleviate investors' fears of a grinding recession, despite an easing in interbank lending rates.
The Dow made another triple digit move on Monday this time soaring more than 400 points higher.
What's an investor to do when he can't depend on that key metric? Here is Cramer's answer.
A nice cash cushion is just what investors need right now, the Mad Money host says. Here's his latest pick.
Following are the “Fast & Furious” trades - hot ways to play next week's market moving events.
A drug stock with a safe dividend? That's just what you need in this tough environment.
Stocks went on another rollercoaster ride Friday, opening sharply lower before a series of ups, downs and curves, and an afternoon burst of bargain hunting that sent the Dow up more than 200 points.
The Dow Industrials has shown some significant moves each day over the past two weeks. In fact, yesterday the Dow was up 10% from its session low to session high.
I don't think Eli Lilly will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration.
In a market as treacherous as this one, that cash cushion could bring the protection you need.
Don't blindly chase this bounce. Be smart and know the playbook to battle the bear.
Of course not! But that's what Fox Business would have you believe. Allow us to set the record straight.
Will history repeat itself? Cramer offers strategies and stocks for surviving the coming week.
Stocks got an early boost from Buffett's vote of confidence in Wall Street but the meandering hearings on the bailout sucked the air out of the trading floor. By the closing bell, financials had fallen and only techs were left carrying the torch of hope.